Health & Environmental Research Online (HERO)


Print Feedback Export to File
7000643 
Journal Article 
AEROSOLIZED PENTAMIDINE PROPHYLAXIS IN HIV-INFECTION - COMPARISON OF 2 NEBULIZE RESPIRGARD-II VERSUS ATOMISOR NL5F 
Fresard, A; Jurus, C; Muron, T; Bertrand, JL; Peyramond, D; Lucht, F; , 
1994 
1 
Medecine et Maladies Infectieuses
ISSN: 0399-077X 
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER 
PARIS 
247-251 
WOS:A1994NK33100004 
In a randomized trial conducted in HIV patients requiring prophylaxis against pneumocystosis, we compared two nebulizers (Respirgard II and Atomisor NL5F). Mass median aerodynamic diameter (MMAD) are comparable for the two nebulizers (Respirgard II - 1,42 mum ; Atomisor NL5F = 1,8 mum). The 76 patients were randomized to one or the other nebulizer. Tolerance was evaluated on clinical criteria : (cough, dyspnea ... ) and on the variation of the peak expiratory flow after each aerosol. The Atomisor NL5F tended to produce more side-effects than the Respirgard II, but the difference was not significant. The best expiratory filter (capacity of retention : 99,97 % for > 0,4 mum diameter particules) of the Atomisor NL5F should reduce the risks of occupational exposure of health care workers and prevent environmental contamination by respiratory pathogens, especially Mycobacterium tuberculosis. The greater risk of aerosolized pentamidine is transmission of tuberculosis from undiagnosed cases. Tuberculose control measures such as improved ventilation and masks should also include the use of nebulizer with high retention expiratory filter.